GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tildacerfont   Click here for help

GtoPdb Ligand ID: 14043

Synonyms: Example 16 [WO2008036579A1] | LY-2371712 | LY2371712 | SPR-001 | SPR001
Compound class: Synthetic organic
Comment: Tildacerfont is a corticotropin-releasing factor (CRF) receptor antagonist. It is proposed to reduce the overproduction of androgens in people with congenital adrenal hyperplasia (CAH), by targeting CRF1 receptor-mediated ACTH secretion. It was designed to address the lipophilicity and associated toxicity liability observed for earlier molecules.
The IUPAC provided for tildacerfont's INN record generates the molecule with the chemical structure shown here and this is same the structure that is associated with CAS registry ID 1014983-00-6 (also provided in the INN record). This has a slightly different structure on the thiazole ring compared to PubChem's entry for tildacerfont (CID 134694266).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 78.09
Molecular weight 419.97
XLogP 3.52
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(CC)C1=CC(=NC2=C(C(=NN12)C)C3=C(Cl)N=C(N4CCOCC4)S3)C
Isomeric SMILES ClC=1N=C(SC1C=2C(=NN3C2N=C(C=C3C(CC)CC)C)C)N4CCOCC4
InChI InChI=1S/C20H26ClN5OS/c1-5-14(6-2)15-11-12(3)22-19-16(13(4)24-26(15)19)17-18(21)23-20(28-17)25-7-9-27-10-8-25/h11,14H,5-10H2,1-4H3
InChI Key XVAWSBAQNIXMIO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Chen Z, Hamdouchi CH, Hembre EJ, Hipskind PA, Myers JK, Takakuwa T, Toth JL. (2008)
Thiazole pyrazolopyrimidines as crf1 receptor antagonists.
Patent number: WO2008036579A1. Assignee: Eli Lilly And Company. Priority date: 17/09/2007. Publication date: 27/03/2008.
2. Sarafoglou K, Barnes CN, Huang M, Imel EA, Madu IJ, Merke DP, Moriarty D, Nakhle S, Newfield RS, Vogiatzi MG et al.. (2021)
Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
J Clin Endocrinol Metab, 106 (11): e4666-e4679. [PMID:34146101]